X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES SUN PHARMA JUBILANT LIFE SCIENCES/
SUN PHARMA
 
P/E (TTM) x 17.0 36.9 46.0% View Chart
P/BV x 4.5 4.1 109.2% View Chart
Dividend Yield % 0.4 0.6 72.5%  

Financials

 JUBILANT LIFE SCIENCES   SUN PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
SUN PHARMA
Mar-17
JUBILANT LIFE SCIENCES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs187842 22.2%   
Low Rs65572 11.4%   
Sales per share (Unadj.) Rs364.3131.6 276.8%  
Earnings per share (Unadj.) Rs6.832.7 20.9%  
Cash flow per share (Unadj.) Rs24.538.0 64.5%  
Dividends per share (Unadj.) Rs3.003.50 85.7%  
Dividend yield (eoy) %2.40.5 481.3%  
Book value per share (Unadj.) Rs164.9152.7 108.0%  
Shares outstanding (eoy) m159.282,399.26 6.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.35.4 6.4%   
Avg P/E ratio x18.421.6 85.1%  
P/CF ratio (eoy) x5.118.6 27.6%  
Price / Book Value ratio x0.84.6 16.5%  
Dividend payout %43.810.7 409.5%   
Avg Mkt Cap Rs m20,0611,696,877 1.2%   
No. of employees `0006.217.5 35.3%   
Total wages/salary Rs m11,05249,023 22.5%   
Avg. sales/employee Rs Th9,383.018,028.3 52.0%   
Avg. wages/employee Rs Th1,786.92,798.8 63.8%   
Avg. net profit/employee Rs Th176.34,479.5 3.9%   
INCOME DATA
Net Sales Rs m58,034315,784 18.4%  
Other income Rs m1916,232 3.1%   
Total revenues Rs m58,224322,016 18.1%   
Gross profit Rs m5,786100,893 5.7%  
Depreciation Rs m2,81212,648 22.2%   
Interest Rs m3,2373,998 81.0%   
Profit before tax Rs m-7290,479 -0.1%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m2,1450-   
Tax Rs m69612,116 5.7%   
Profit after tax Rs m1,09078,462 1.4%  
Gross profit margin %10.031.9 31.2%  
Effective tax rate %-965.913.4 -7,213.1%   
Net profit margin %1.924.8 7.6%  
BALANCE SHEET DATA
Current assets Rs m29,280329,537 8.9%   
Current liabilities Rs m38,912178,870 21.8%   
Net working cap to sales %-16.647.7 -34.8%  
Current ratio x0.81.8 40.8%  
Inventory Days Days8479 106.8%  
Debtors Days Days5183 60.9%  
Net fixed assets Rs m55,712204,766 27.2%   
Share capital Rs m1552,399 6.4%   
"Free" reserves Rs m20,968363,997 5.8%   
Net worth Rs m26,265366,397 7.2%   
Long term debt Rs m17,16914,361 119.6%   
Total assets Rs m88,606614,102 14.4%  
Interest coverage x1.023.6 4.1%   
Debt to equity ratio x0.70 1,667.8%  
Sales to assets ratio x0.70.5 127.4%   
Return on assets %4.913.4 36.4%  
Return on equity %4.221.4 19.4%  
Return on capital %11.624.8 46.6%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00444,118 49.9%   
Fx outflow Rs m11,74924,484 48.0%   
Net fx Rs m10,25519,634 52.2%   
CASH FLOW
From Operations Rs m8,02670,822 11.3%  
From Investments Rs m-1,744-42,216 4.1%  
From Financial Activity Rs m-4,447-22,854 19.5%  
Net Cashflow Rs m1,8346,107 30.0%  

Share Holding

Indian Promoters % 45.6 63.7 71.6%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 5.1 169.6%  
FIIs % 21.2 23.0 92.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 8.3 254.2%  
Shareholders   23,815 133,026 17.9%  
Pledged promoter(s) holding % 15.9 0.5 2,990.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 17, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS